Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors

201595 citationsJournal Article

Authors

Good health and well-being

Published in: Cancer Chemotherapy and Pharmacology

Volume 76, Issue 6, pp. 1143-1152

Field-Weighted Citation Impact: 4.52